YGYi Sing Gee

Yi Sing Gee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi Sing Gee has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fanconi Anaemia E3 Ligase complex activity is regulated by a druggable metabolite binding site in FANCX

    by Michael F Sharp, Yi Sing Gee, Jennii Luu, Karla J. Cowley, Henry Beetham, Christopher G. Langendorf, Jonathan S. Oakhill, John W Scott, Debora Cavero, Jordi Minguillon, et al.

    The Fanconi anaemia (FA) DNA repair pathway is an emerging target for precision cancer therapy. Using a high-throughput FANCD2-monoubiquitination assay, we identified a class of small molecules, including MSG010, that inhibit the FA E3 ligase complex in vitro . Because these molecules, and the metabolite, palmitoyl-CoA, are known to engage allosteric drug and metabolite (ADaM) binding site in AMP-activated kinase (AMPK), we hypothesised that a similar pocket exists within the FA complex. Supporting this, long-chain, but not short-chain, fatty acyl-CoA molecules inhibited the FA E3 ligase complex activity, and sequence analysis revealed similarity between the AMPK ADaM site and a WD40 repeat in the FA subunit FANCX. Targeted mutagenesis of this FANCX region disrupted E3 ligase activity or abolished inhibition by MSG010, suggesting the presence of an ADaM-like site in FANCX. Moreover, MSG010 preferentially killed BRCA1 -deficient cells in vitro . These findings identify a putative small-molecule binding site in the FA pathway that may be developed further to test for exploitation as anticancer therapeutics.

  • Open Access

    Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids

    by Joel L. Syphers, Josephine A. Wright, Rebekah de Nys, Tharindie N. Silva, Laura Vrbanac, Kate R. Barratt, Julia Leeflang, Sadia T. Hasan, Sophie F. Thomson, Adarsh Kumar, et al.


  • Open Access

    Biological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes

    by Adi Suwandi, Jianwen Jin, Yichao Zhao, Ramesh Mudududdla, Yi Sing Gee, Girdhar Singh Deora, Yuxin Sun, Heping Wei, Fei Huang, Jin-Shu He, et al.

    All lysine acetyltransferases (KATs) modulate biological outcomes through the acetylation of lysine side-chain amino groups facilitated by acetyl coenzyme A (AcCoA). KAT6A belongs to the class of MYST domain histone acetyltransferases (HATs), which had been regarded as undruggable. The first on-target KAT6A inhibitors with in vivo activity were reported in 2018, catalyzing intense industry interest in this enzyme as an oncology target. In this study, we experimentally evaluated representative KAT6A inhibitor chemotypes through resynthesis and comparative biochemical assays, cellular assays, and structural biology. We outline the recent history of each KAT6A inhibitor chemotype discovery, including SAR for potency, selectivity, and cellular activity. We extensively benchmark key compounds from each chemotype, augmented by new acylsulfonohydrazide analogues and a novel fused [1,2,4]thiadiazine KAT6A inhibitor subclass, which we report here for the first time, along with co-crystal structures. Additionally, we report on the in vivo activity, pharmacokinetics, and toxicology profiles of these inhibitors.


  • Nitroreductase-Activated Probes for Monitoring Hypoxia

    by Eric Tran, Zijie Luo, Andrew Xi-Yuan Tang, Chuhui Huang, Yi Sing Gee, Jonathan Baell, Amandeep Kaur, Manuela Jörg

    Hypoxia, a hallmark of solid tumors, complicates cancer treatment by reducing the efficacy of radiotherapy and chemotherapy. To optimize strategies for hypoxia detection and targeted cancer therapy, this work explores the development of hypoxia-responsive fluorescent probes. In this study, we compared various nitroaromatic groups and both elimination-based and cyclization-based self-immolative designs to study nitroreductase (NTR) activation. The research highlighted differences in activation response among the probes, with elimination-based probes (8b-8d) showing faster activation compared to cyclization-based probes (8f-8i). Furthermore, analogs with different nitroaromatic linkers exhibited different selectivity profiles for common biomolecules and ions. These subtle differences were also apparent in our cellular hypoxia assays, underscoring the importance of carefully selecting the nitroaromatic moiety and probe/drug design for applications such as diagnostic tools to detect hypoxia or targeted cancer therapies.


  • Open Access

    Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis

    by Eric Tran, Chen‐Yi Cheung, Lucy Li, Glen P. Carter, Robert W. Gable, Nicholas P. West, Amandeep Kaur, Yi Sing Gee, Gregory M. Cook, Jonathan B. Baell, et al.

    Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F420 biosynthesis (fbiC), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.


  • Open Access

    Novel dual‐action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine‐specific histone demethylase 1A inhibitor

    by Martin Engel, Yi Sing Gee, Dale Cross, Alan Maccarone, Benjamin Heng, Amy Hulme, Grady Smith, Gilles J. Guillemin, Brett W. Stringer, Christopher J. T. Hyland, et al.

    Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsuccessful against glioblastoma (GBM). Altered histone 3 lysine 4 methylation and increased lysine‐specific histone demethylase 1A (LSD1) expression in GBM tumours nonetheless suggest that epigenetic mechanisms are involved in GBM. We engineered a dual‐action prodrug, which is activated by the high hydrogen peroxide levels associated with GBM cells. This quinone methide phenylaminecyclopropane prodrug releases the LSD1 inhibitor 2‐phenylcyclopropylamine with the glutathione scavenger para‐quinone methide to trigger apoptosis in GBM cells. Quinone methide phenylaminocyclopropane impaired GBM cell behaviours in two‐dimensional and three‐dimensional assays, and triggered cell apoptosis in several primary and immortal GBM cell cultures. These results support our double‐hit hypothesis of potentially targeting LSD1 and quenching glutathione, in order to impair and kill GBM cells but not healthy astrocytes. Our data suggest this strategy is effective at selectively targeting GBM and potentially other types of cancers.Open science badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. image


  • Pd-Catalyzed Dearomative [3 + 2] Cycloaddition of 3-Nitroindoles with 2-Vinylcyclopropane-1,1-dicarboxylates

    by Yi Sing Gee, Daniel J. Rivinoja, Steven M. Wales, Michael G. Gardiner, John H. Ryan, Christopher J. T. Hyland

    A trans-diastereoselective Pd-catalyzed dearomative [3 + 2] cycloaddition between vinylcyclopropane dicarboxylates and 3-nitroindoles has been developed. The reaction provides densely functionalized cyclopenta[b]indolines with versatile vinyl and nitro-groups. The addition of a halide additive was found to be critical for the diastereoselectivity of the reaction, which is proposed to be a result of a rapid π-σ-π interconversion between the intermediates allowing for Curtin–Hammett control. A switch in diastereoselectivity to afford products with the vinyl and nitro groups cis to each other is observed with a 4-substituted 3-nitroindole.


  • Oxidative ring-opening of ferrocenylcyclopropylamines to N-ferrocenylmethyl β-hydroxyamides

    by Yi Sing Gee, Neils J. M. Goertz, Michael G. Gardiner, Christopher J. T. Hyland

    The in situ reduction of ferrocenyl cyclopropylimines to the corresponding amines triggers a facile oxidative ring-opening to yield the formal four-electron oxidation products: N-ferrocenylmethyl β-hydroxyamides. This process is believed to proceed via generation of a ferrocinium ion in the presence of air, leading to facile formation of a distonic radical cation that is ultimately trapped by oxygen.


  • Synthetic methods: part (ii) oxidation and reduction methods

    by Yi Sing Gee, Kamelia Fathy Abd El Kader, Christopher J. T. Hyland

    This report highlights selected advances in some of the most commonly used oxidation and reduction reactions, focusing on the literature from 2012. The structure of this review follows that of the previous years report (J. K. Howard and C. J. T. Hyland, Annu. Rep. Prog. Chem., Sect. B: Org. Chem., 2012, 108, 29–52 (). In the field of oxidation a number of important advances have been made. Notably, the group of Miller has reported a peptide-based catalyst that allows the selective epoxidation of polyenes (P. A. Lichtor and S. J. Miller, Nat. Chem., 2012, 4, 990). Meanwhile, the Tomkinson group has reported osmium-free alkene dihydroxylation reactions with cyclopropyl-derived malonoyl peroxides (S. Picon, M. Rawling, M. Campbell and N. C. O. Tomkinson, Org. Lett., 2012, 14, 6250–6253). In the area of reduction methods the Chirik group has made an exciting breakthrough in the use of non-precious metal enantiopure C1-symmetric bis(imino)pyridine cobalt complexes for asymmetric hydrogenation of a range of styrene derivatives in up to 96% ee (S. Monfette, Z. R. Turner, S. P. Semproni and P. J. Chirik, J. Am. Chem. Soc., 2012, 134, 4561–4564). Meanwhile Kuwano et al. have reported the first PhTrap-ruthenium catalysed asymmetric hydrogenation of naphthalenes (R. Kuwano, R. Morioka, M. Kashiwabara and N. Kameyama, Angew. Chem., Int. Ed., 2012, 51, 4136–4139).